Pacific Biosciences of California PACB Product revenue — Cost of revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's product revenue — cost of revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's product revenue — cost of revenue?
- Pacific Biosciences of California (PACB) reported product revenue — cost of revenue of $19.97M in Q1 2026.
- How has Pacific Biosciences of California's product revenue — cost of revenue changed year-over-year?
- Pacific Biosciences of California's product revenue — cost of revenue decreased by 24.2% year-over-year, from $26.33M to $19.97M.
- What is the long-term trend for Pacific Biosciences of California's product revenue — cost of revenue?
- Over 4 years (2021 to 2025), Pacific Biosciences of California's product revenue — cost of revenue has grown at a 12.3% compound annual growth rate (CAGR), from $56.36M to $89.76M.
- What does product revenue — cost of revenue mean?
- This metric captures the direct costs associated with manufacturing and delivering the physical products sold by the company, including raw materials, labor, and overhead directly attributable to production. It is a critical measure of the company's manufacturing efficiency and the direct cost burden of its hardware and consumable sales. Analyzing this metric allows stakeholders to evaluate gross margin trends and the scalability of the company's production processes.